ARROWHEAD PHARMACEUTICALS, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $466.04 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $466.04M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $598.92M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $562.70M.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $503.42M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2026-06-30 | $466.04M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $598.92M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $562.70M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $503.42M 10-Q · filed 2026-08-04 | |
| 2025-06-30 | $519.81M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $684.23M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $56.08M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $191.06M 10-Q · filed 2026-08-04 | |
| 2024-06-30 | $338.97M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $495.40M 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $173.71M 10-Q · filed 2025-08-07 | |
| 2023-09-30 | $287.16M 10-K · filed 2025-11-25 | |
| 2023-06-30 | $381.99M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $465.11M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $396.37M 10-Q · filed 2024-08-08 | |
| 2022-09-30 | $418.34M 10-K · filed 2025-11-25 | |
| 2022-06-30 | $474.18M 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $452.27M 10-Q · filed 2023-08-07 | |
| 2021-12-31 | $372.56M 10-Q · filed 2023-08-07 | |
| 2021-09-30 | $408.82M 10-K · filed 2024-11-26 | |
| 2021-06-30 | $436.89M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $445.55M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $454.47M 10-Q · filed 2022-05-10 | |
| 2020-09-30 | $461.78M 10-K · filed 2023-11-29 | $461.78M 10-K · filed 2020-11-23 |
| 2020-06-30 | $492.58M 10-Q · filed 2021-08-05 | $492.59M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $493.56M 10-Q · filed 2021-08-05 | $493.56M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $499.53M 10-Q · filed 2021-05-04 | $499.53M 10-Q · filed 2020-02-05 |
| 2019-09-30 | $244.04M 10-K · filed 2022-11-28 | $244.04M 10-K · filed 2019-11-25 |
| 2019-06-30 | $225.67M 10-Q · filed 2020-08-05 | |
| 2019-03-31 | $200.64M 10-Q · filed 2020-08-05 | $200.64M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $171.50M 10-Q · filed 2020-05-07 | |
| 2018-09-30 | $95.24M 10-K · filed 2021-11-22 | $95.24M 10-K · filed 2018-12-11 |
| 2018-06-30 | $101.76M 10-Q · filed 2019-08-05 | |
| 2018-03-31 | $113.72M 10-Q · filed 2019-08-05 | $113.72M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $70.20M 10-Q · filed 2019-05-08 | |
| 2017-09-30 | $80.87M 10-K · filed 2020-11-23 | |
| 2017-06-30 | $89.54M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $93.34M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $97.21M 10-Q · filed 2017-02-06 | |
| 2016-09-30 | $95.02M 10-K · filed 2019-11-25 | |
| 2016-06-30 | $59.43M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $73.93M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $92.37M 10-Q · filed 2016-02-09 | |
| 2015-09-30 | $109.62M 10-K · filed 2018-12-11 | |
| 2015-06-30 | $130.74M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $144.20M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $145.71M 10-Q · filed 2015-02-09 | |
| 2014-09-30 | $165.99M 10-K · filed 2017-12-12 | |
| 2014-06-30 | $185.81M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $189.54M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $80.91M 10-Q · filed 2014-02-04 | |
| 2013-09-30 | $25.73M 10-K · filed 2016-12-14 | |
| 2013-06-30 | $33.31M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $3.76M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $7.60M 10-Q · filed 2013-02-13 | |
| 2012-09-30 | $8.81M 10-K · filed 2015-12-14 | |
| 2012-06-30 | $8.45M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $11.57M 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $15.75M 10-Q · filed 2012-02-09 | |
| 2011-09-30 | $12.56M 10-K · filed 2014-11-25 | $12.56M 10-K · filed 2011-12-20 |
| 2011-06-30 | $10.57M 10-Q · filed 2011-08-08 | |
| 2010-09-30 | $8.08M 10-Q · filed 2014-05-06 | $8.08M 10-Q · filed 2011-08-08 |
| 2009-09-30 | $4.86M 10-Q · filed 2014-05-06 | |
| 2008-09-30 | $12.30M 10-Q · filed 2014-05-06 | |
| 2007-09-30 | $26.46M 10-Q · filed 2014-05-06 | |
| 2006-09-30 | $31.61M 10-Q · filed 2014-05-06 | |
| 2005-09-30 | $28.03M 10-Q · filed 2014-05-06 | |
| 2004-09-30 | $11.23M 10-Q · filed 2014-05-06 | |
| 2003-09-30 | $1.42M 10-Q · filed 2014-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |